Epoch Investment Partners Inc. Acquires 15,133 Shares of Chemed Corporation $CHE

Epoch Investment Partners Inc. lifted its holdings in shares of Chemed Corporation (NYSE:CHEFree Report) by 4.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 322,408 shares of the company’s stock after acquiring an additional 15,133 shares during the period. Epoch Investment Partners Inc.’s holdings in Chemed were worth $137,945,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Chemed by 61.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 154,519 shares of the company’s stock worth $66,112,000 after acquiring an additional 58,946 shares during the period. Aptus Capital Advisors LLC lifted its holdings in shares of Chemed by 1.3% during the 4th quarter. Aptus Capital Advisors LLC now owns 57,381 shares of the company’s stock worth $24,551,000 after acquiring an additional 757 shares during the period. FORA Capital LLC bought a new position in shares of Chemed during the 4th quarter worth about $795,000. Kestra Advisory Services LLC lifted its holdings in shares of Chemed by 13.8% during the 4th quarter. Kestra Advisory Services LLC now owns 1,748 shares of the company’s stock worth $748,000 after acquiring an additional 212 shares during the period. Finally, Johnson Investment Counsel Inc. lifted its holdings in shares of Chemed by 0.6% during the 4th quarter. Johnson Investment Counsel Inc. now owns 8,764 shares of the company’s stock worth $3,750,000 after acquiring an additional 50 shares during the period. 95.85% of the stock is owned by institutional investors.

Chemed Trading Down 0.4%

Shares of CHE stock opened at $419.07 on Friday. Chemed Corporation has a 12-month low of $365.20 and a 12-month high of $562.77. The company has a market capitalization of $5.56 billion, a P/E ratio of 22.84, a P/E/G ratio of 1.57 and a beta of 0.54. The firm has a 50-day moving average price of $415.27 and a 200 day moving average price of $424.51. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11.

Chemed (NYSE:CHEGet Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The firm had revenue of $657.51 million during the quarter, compared to the consensus estimate of $659.22 million. During the same period last year, the firm posted $5.63 EPS. The firm’s quarterly revenue was up 1.6% on a year-over-year basis. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Research analysts forecast that Chemed Corporation will post 22.3 earnings per share for the current fiscal year.

Chemed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.6%. The ex-dividend date is Thursday, May 28th. Chemed’s dividend payout ratio (DPR) is presently 13.08%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Weiss Ratings raised shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Royal Bank Of Canada lifted their price target on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a report on Monday, April 27th. Wall Street Zen downgraded shares of Chemed from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Oppenheimer cut their price target on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Chemed presently has an average rating of “Hold” and an average price target of $501.50.

Check Out Our Latest Stock Report on Chemed

Insider Activity

In other Chemed news, Director Andrea R. Lindell sold 1,347 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total value of $602,553.51. Following the completion of the sale, the director owned 4,578 shares in the company, valued at approximately $2,047,876.74. This trade represents a 22.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the completion of the sale, the chief executive officer owned 90,219 shares of the company’s stock, valued at $37,993,927.47. The trade was a 2.17% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 3.33% of the company’s stock.

About Chemed

(Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

See Also

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHEFree Report).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.